Source: European Medicines Agency (EU) Revision Year: 2017 Publisher: PharmaSwiss Česká republika s.r.o., Jankovcova 1569/2c, 170 00, Praha 7, Czech republic
Relistor 12 mg/0.6 mL solution for injection.
Pharmaceutical Form |
---|
Solution for injection. Clear solution, colourless to pale-yellow, essentially free from visible particulates. |
Each vial of 0.6 mL contains 12 mg of methylnaltrexone bromide.
One mL of solution contains 20 mg of methylnaltrexone bromide.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Methylnaltrexone |
Methylnaltrexone bromide is a selective antagonist of opioid binding at the mu-receptor. As a quaternary amine, the ability of methylnaltrexone bromide to cross the blood-brain barrier is restricted. This allows methylnaltrexone bromide to function as a peripherally acting mu-opioid antagonist in tissues such as the gastrointestinal tract, without impacting opioid-mediated analgesic effects on the central nervous system. |
List of Excipients |
---|
Sodium chloride |
Clear, Type I, flint glass, single-use vial, grey butyl rubber stopper, and aluminium overseal with flip-off-cap.
Each vial contains 0.6 mL of solution for injection.
Pack sizes of:
Not all pack sizes may be marketed.
PharmaSwiss Česká republika s.r.o., Jankovcova 1569/2c, 170 00, Praha 7, Czech republic
EU/1/08/463/001
EU/1/08/463/002
EU/1/08/463/003
Date of first authorisation: 02 July 2008
Date of latest renewal: 27 May 2013
Drug | Countries | |
---|---|---|
RELISTOR | Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.